Acrux Limited has released a press release.
Investor Presentation - Female Testosterone for HSDD
Earlier from Acrux
- Update - Licensing Lenzetto for Australia for AUD5.4m
- Acrux licenses Lenzetto for Australian market for AUD5.4m
- Capital Gains Tax exemptions remain in place for Acrux
- Acrux raises $1.6 million via Share Placement